Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection
This study has been completed.
Study NCT00000793 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999 Last Updated: June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Peripheral Nervous System Disease
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
Infection
Nervous System Diseases
Peripheral Nervous System Diseases
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Neuromuscular Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Mexiletine hydrochloride
Benztropine mesylate
Amitriptyline hydrochloride
Additional drug interventions recognized in this trial
Amitriptyline
Benztropine
Mexiletine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Analgesics
Analgesics, Non-Narcotic
Anti-Arrhythmia Agents
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Tricyclic
Antiparkinson Agents
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Boehringer Ingelheim Pharmaceuticals
Back to top of Main Content
